/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Insperity Announces Record First Quarter Results
HOUSTON–(BUSINESS WIRE)–Insperity,
Inc. (NYSE: NSP), a leading provider of human
resources and business performance solutions for America’s best
businesses, today reported results for the first quarter ended Mar. 31,
2019:
- Q1 WSEE growth of 15% on strong sales and client retention
-
Q1 net income and EPS up 53% and 57%, to $76 million and $1.85,
respectively - Q1 adjusted EPS up 40% to $1.98
- Q1 adjusted EBITDA up 21% to $101 million
First Quarter Results
First quarter 2019 net income and diluted earnings per share of $76.3
million and $1.85 represented increases of 53% and 57%, respectively,
compared to the first quarter of 2018. Adjusted EPS was $1.98, a 40%
increase over the first quarter of 2018. Adjusted EBITDA increased 21%
over the first quarter of 2018 to $101.4 million.
“Our record first quarter results reflect the strength of our business
model and continued excellent execution of our strategic plan,” said
Paul J. Sarvadi, Insperity chairman and chief executive officer. “These
results further demonstrate the sustainability of our rapid growth and
profitability experienced over the last several years into 2019.”
Revenues increased 14% over the first quarter of 2018 to $1,153.0
million on a 15% increase in the average number of worksite employees
(“WSEEs”) paid per month. The continued double-digit worksite employee
growth was the result of the enrollment of new clients coming off a
successful 2018 fall sales campaign and a high level of client retention
during our heavy first quarter client renewal period. Additionally, we
experienced net hiring in our client base during the first quarter of
2019, although at lower levels than experienced during the first quarter
of 2018.
Gross profit increased 14% over the first quarter of 2018 to $226.7
million, and included favorable workers’ compensation and benefit cost
trends and stronger pricing. Operating expenses increased 5% over the
first quarter of 2018, while adjusted operating expenses increased 12%
to $141.3 million, and included continued investments in our growth,
technology and product and service offerings.
“Worksite employee growth in the mid-teens, combined with effective
management of pricing, direct cost programs and operating costs,
produced adjusted EBITDA and cash flow at record levels,” said Douglas
S. Sharp, senior vice president of finance, chief financial officer and
treasurer. “We ended the first quarter with $141 million of adjusted
cash, up from $129 million at December 31, 2018, after the repurchase of
230,000 shares at a cost of $29 million and the payment of our regular
cash dividend totaling $12 million.”
2019 Guidance
The company also announced its updated guidance for 2019, including the
second quarter of 2019. Please refer to the accompanying financial
tables at the end of this press release for the reconciliation of
non-GAAP financial measures to the comparable GAAP financial measures.
Q2 2019 | Full Year 2019 | ||||||||||||||
Average WSEEs paid | 232,500 | — | 234,500 | 238,400 | — | 242,600 | |||||||||
Year-over-year increase | 14.0% | — | 15.0% | 14.0% | — | 16.0% | |||||||||
Adjusted EPS | $0.81 | — | $0.86 | $4.55 | — | $4.80 | |||||||||
Year-over-year increase | 19% | — | 26% | 21% | — | 28% | |||||||||
Adjusted EBITDA (in millions) | $55 | — | $58 | $276 | — | $289 | |||||||||
Year-over-year increase | 18% | — | 24% | 15% | — | 21% | |||||||||
Definition of Key Metrics
Average WSEEs paid – Determined by calculating the company’s cumulative
worksite employees paid during the period divided by the number of
months in the period.
Adjusted EPS – Represents diluted net income per share computed in
accordance with GAAP, excluding the impact of non-cash stock-based
compensation and costs associated with a one-time tax reform bonus paid
to corporate employees.
Adjusted EBITDA – Represents net income computed in accordance with
GAAP, plus interest expense, income taxes, depreciation and amortization
expense, non-cash stock-based compensation and costs associated with a
one-time tax reform bonus paid to corporate employees.
Insperity will be hosting a conference call today at 10 a.m. ET to
discuss these results, provide guidance for the second quarter and an
update to the full year guidance, and answer questions from investment
analysts. To listen in, call 877-651-0053 and use conference i.d. number
2122429. The call will also be webcast at http://ir.insperity.com.
The conference call script will be available at the same website later
today. A replay of the conference call will be available at
855-859-2056, conference i.d. 2122429. The webcast will be archived for
one year.
About Insperity
Insperity, a trusted advisor to America’s best businesses for more than
33 years, provides an array of human resources and business solutions
designed to help improve business performance. Insperity® Business
Performance Advisors offer the most comprehensive suite of products and
services available in the marketplace. Insperity delivers administrative
relief, better benefits, reduced liabilities and a systematic way to
improve productivity through its premier Workforce Optimization®
solution. Additional company offerings include Traditional Payroll and
Human Capital Management, Time and Attendance, Performance Management,
Organizational Planning, Recruiting Services, Employment Screening,
Expense Management, Retirement Services and Insurance Services.
Insperity business performance solutions support more than 100,000
businesses with over 2 million employees. With 2018 revenues of $3.8
billion, Insperity operates in 74 offices throughout the United States.
For more information, visit http://www.insperity.com.
Forward-Looking Statements
The statements contained herein that are not historical facts are
forward-looking statements within the meaning of the federal securities
laws (Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934). You can identify such forward-looking
statements by the words “expects,” “intends,” “plans,” “projects,”
“believes,” “estimates,” “likely,” “possibly,” “probably,” “goal,”
“opportunity,” “objective,” “target,” “assume,” “outlook,” “guidance,”
“predicts,” “appears,” “indicator” and similar expressions.
Forward-looking statements involve a number of risks and uncertainties.
In the normal course of business, Insperity, Inc., in an effort to help
keep our stockholders and the public informed about our operations, may
from time to time issue such forward-looking statements, either orally
or in writing. Generally, these statements relate to business plans or
strategies, projected or anticipated benefits or other consequences of
such plans or strategies, or projections involving anticipated revenues,
earnings, unit growth, profit per worksite employee, pricing, operating
expenses or other aspects of operating results. We base the
forward-looking statements on our expectations, estimates and
projections at the time such statements are made. These statements are
not guarantees of future performance and involve risks and uncertainties
that we cannot predict. In addition, we have based many of these
forward-looking statements on assumptions about future events that may
prove to be inaccurate. Therefore, the actual results of the future
events described in such forward-looking statements could differ
materially from those stated in such forward-looking statements. Among
the factors that could cause actual results to differ materially are:
- adverse economic conditions;
-
regulatory and tax developments and possible adverse application of
various federal, state and local regulations; -
the ability to secure competitive replacement contracts for health
insurance and workers’ compensation insurance at expiration of current
contracts; -
cancellation of client contracts on short notice, or the inability to
renew client contracts or attract new clients; -
vulnerability to regional economic factors because of our geographic
market concentration; -
increases in health insurance costs and workers’ compensation rates
and underlying claims trends, health care reform, financial solvency
of workers’ compensation carriers, other insurers or financial
institutions, state unemployment tax rates, liabilities for employee
and client actions or payroll-related claims; -
failure to manage growth of our operations and the effectiveness of
our sales and marketing efforts; -
the impact of the competitive environment and other developments in
the human resources services industry, including the PEO industry, on
our growth and/or profitability; -
our liability for worksite employee payroll, payroll taxes and
benefits costs; - our liability for disclosure of sensitive or private information;
-
our ability to integrate or realize expected returns on our
acquisitions; - failure of our information technology systems;
-
an adverse final judgment or settlement of claims against Insperity;
and -
disruptions to our business resulting from the actions of certain
stockholders.
These factors are discussed in further detail in Insperity’s filings
with the U.S. Securities and Exchange Commission. Any of these factors,
or a combination of such factors, could materially affect the results of
our operations and whether forward-looking statements we make ultimately
prove to be accurate.
Except to the extent otherwise required by federal securities law, we do
not undertake any obligation to update our forward-looking statements to
reflect events or circumstances after the date they are made or to
reflect the occurrence of unanticipated events.
Insperity, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) |
||||||||||
(in thousands) | March 31, 2019 | December 31, 2018 | ||||||||
Assets | ||||||||||
Cash and cash equivalents | $ | 398,936 | $ | 326,773 | ||||||
Restricted cash | 44,705 | 42,227 | ||||||||
Marketable securities | 53,599 | 60,781 | ||||||||
Accounts receivable, net | 421,297 | 400,623 | ||||||||
Prepaid insurance | 24,928 | 8,411 | ||||||||
Other current assets | 36,616 | 27,721 | ||||||||
Total current assets | 980,081 | 866,536 | ||||||||
Property and equipment, net | 116,131 | 117,213 | ||||||||
Right of use leased assets | 50,259 | — | ||||||||
Prepaid health insurance | 9,000 | 9,000 | ||||||||
Deposits | 177,105 | 172,674 | ||||||||
Goodwill and other intangible assets, net | 12,723 | 12,726 | ||||||||
Deferred income taxes, net | 145 | 8,816 | ||||||||
Other assets | 5,534 | 4,851 | ||||||||
Total assets | $ | 1,350,978 | $ | 1,191,816 | ||||||
Liabilities and stockholders’ equity | ||||||||||
Accounts payable | $ | 7,854 | $ | 10,622 | ||||||
Payroll taxes and other payroll deductions payable | 308,062 | 261,166 | ||||||||
Accrued worksite employee payroll cost | 363,862 | 329,979 | ||||||||
Accrued health insurance costs | 45,832 | 35,153 | ||||||||
Accrued workers’ compensation costs | 47,973 | 45,818 | ||||||||
Accrued corporate payroll and commissions | 27,562 | 60,704 | ||||||||
Other accrued liabilities | 49,244 | 28,890 | ||||||||
Total current liabilities | 850,389 | 772,332 | ||||||||
Accrued workers’ compensation cost, net of current | 186,624 | 187,412 | ||||||||
Long-term debt | 144,400 | 144,400 | ||||||||
Operating lease liabilities, net of current | 50,371 | — | ||||||||
Other accrued liabilities, net of current | — | 9,996 | ||||||||
Total noncurrent liabilities | 381,395 | 341,808 | ||||||||
Stockholders’ equity: | ||||||||||
Common stock | 555 | 555 | ||||||||
Additional paid-in capital | 33,833 | 36,752 | ||||||||
Treasury stock, at cost | (376,097 | ) | (357,569 | ) | ||||||
Retained earnings | 460,903 | 397,938 | ||||||||
Total stockholders’ equity | 119,194 | 77,676 | ||||||||
Total liabilities and stockholders’ equity | $ | 1,350,978 | $ | 1,191,816 |
Insperity, Inc. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) |
||||||||||||
Three Months Ended March 31, |
||||||||||||
(in thousands, except per share amounts) | 2019 | 2018 | Change | |||||||||
Operating results: | ||||||||||||
Revenues(1) | $ | 1,153,010 | $ | 1,014,372 | 13.7 | % | ||||||
Payroll taxes, benefits and workers’ compensation costs | 926,293 | 814,652 | 13.7 | % | ||||||||
Gross profit | 226,717 | 199,720 | 13.5 | % | ||||||||
Salaries, wages and payroll taxes | 83,380 | 87,186 | (4.4 | )% | ||||||||
Stock-based compensation | 6,040 | 3,135 | 92.7 | % | ||||||||
Commissions | 6,952 | 6,066 | 14.6 | % | ||||||||
Advertising | 5,031 | 3,565 | 41.1 | % | ||||||||
General and administrative expenses | 33,162 | 29,852 | 11.1 | % | ||||||||
Depreciation and amortization | 6,691 | 5,213 | 28.4 | % | ||||||||
Total operating expenses | 141,256 | 135,017 | 4.6 | % | ||||||||
Operating income | 85,461 | 64,703 | 32.1 | % | ||||||||
Other income (expense): | ||||||||||||
Interest income | 3,245 | 1,456 | 122.9 | % | ||||||||
Interest expense | (1,681 | ) | (1,070 | ) | 57.1 | % | ||||||
Income before income tax expense | 87,025 | 65,089 | 33.7 | % | ||||||||
Income tax expense | 10,736 | 15,098 | (28.9 | )% | ||||||||
Net income | $ | 76,289 | $ | 49,991 | 52.6 | % | ||||||
Less distributed and undistributed earnings allocated to participating securities |
(1,031 | ) | (585 | ) | 76.2 | % | ||||||
Net income allocated to common shares | $ | 75,258 | $ | 49,406 | 52.3 | % | ||||||
Net income per share of common stock | ||||||||||||
Basic | $ | 1.86 | $ | 1.20 | 55.0 | % | ||||||
Diluted | $ | 1.85 | $ | 1.18 | 56.8 | % |
____________________________________ | ||
(1) |
Revenues are comprised of gross billings less WSEE payroll costs as follows: |
Three Months Ended March 31, | ||||||||||||
(in thousands) | 2019 | 2018 | ||||||||||
Gross billings | $ | 6,871,670 | $ | 5,923,356 | ||||||||
Less: WSEE payroll cost | 5,718,660 | 4,908,984 | ||||||||||
Revenues | $ | 1,153,010 | $ | 1,014,372 |
Insperity, Inc. KEY FINANCIAL AND STATISTICAL DATA (Unaudited) |
||||||||||||||
Three Months Ended March 31, | ||||||||||||||
2019 | 2018 | Change | ||||||||||||
Average WSEEs paid | 225,525 | 195,683 | 15.3 | % | ||||||||||
Statistical data (per WSEE per month): | ||||||||||||||
Revenues(1) | $ | 1,704 | $ | 1,728 | (1.4 | )% | ||||||||
Gross profit | 335 | 340 | (1.5 | )% | ||||||||||
Operating expenses | 209 | 230 | (9.1 | )% | ||||||||||
Operating income | 126 | 110 | 14.5 | % | ||||||||||
Net income | 113 | 85 | 32.9 | % |
____________________________________ | ||
(1) |
Revenues per WSEE per month are comprised of gross billings per WSEE per month less WSEE payroll costs per WSEE per month follows: |
Three Months Ended March 31, | ||||||||||||
(per WSEE per month) | 2019 | 2018 | ||||||||||
Gross billings | $ | 10,157 | $ | 10,090 | ||||||||
Less: WSEE payroll cost | 8,453 | 8,362 | ||||||||||
Revenues | $ | 1,704 | $ | 1,728 |
Insperity, Inc. Non-GAAP Financial Measures (Unaudited) |
Non-GAAP financial measures are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of the non-GAAP financial measures used to their most directly comparable GAAP financial measures as provided in the tables below. |
Non-GAAP Measure | Definition | Benefit of Non-GAAP Measure | ||||
Non-bonus payroll cost |
Non-bonus payroll cost is a non-GAAP financial measure that excludes the impact of bonus payrolls paid to our WSEEs.
Bonus payroll cost varies from period to period, but has no direct |
Our management refers to non-bonus payroll cost in analyzing, reporting and forecasting our workers’ compensation costs.
We include these non-GAAP financial measures because we believe |
||||
Adjusted cash, cash equivalents and marketable securities |
Excludes funds associated with:
• federal and state income tax withholdings, • employment taxes, • other payroll deductions, and • client prepayments. |
We believe that the exclusion of the identified items helps us reflect the fundamentals of our underlying business model and analyze results against our expectations, against prior period, and to plan for future periods by focusing on our underlying operations. We believe that the adjusted results provide relevant and useful information for investors because they allow investors to view performance in a manner similar to the method used by management and improves their ability to understand and assess our operating performance. |
||||
Adjusted operating expense |
Represents operating expenses excluding the impact of the following:
• costs associated with a one-time tax reform bonus paid to |
|||||
EBITDA |
Represents net income computed in accordance with GAAP, plus:
• interest expense, • income tax expense, and • depreciation and amortization expense. |
|||||
Adjusted EBITDA |
Represents EBITDA plus:
• non-cash stock based compensation, and
• costs associated with a one-time tax reform bonus paid to |
|||||
Adjusted Net Income |
Represents net income computed in accordance with GAAP, excluding:
• non-cash stock based compensation, and
• costs associated with a one-time tax reform bonus paid to |
|||||
Adjusted EPS |
Represents diluted net income per share computed in accordance with GAAP, excluding: • non-cash stock based compensation, and
• costs associated with a one-time tax reform bonus paid to |
|||||
Following is a reconciliation of payroll cost (GAAP) to non-bonus
payroll costs (non-GAAP):
Three Months Ended March 31, | ||||||||||||||||||
(in thousands, except per WSEE per month) | 2019 | 2018 | ||||||||||||||||
$ | WSEE | $ | WSEE | |||||||||||||||
Payroll cost | $ | 5,718,660 | $ | 8,453 | $ | 4,908,984 | $ | 8,362 | ||||||||||
Less: Bonus payroll cost | 990,578 | 1,465 | 830,861 | 1,415 | ||||||||||||||
Non-bonus payroll cost | $ | 4,728,082 | $ | 6,988 | $ | 4,078,123 | $ | 6,947 | ||||||||||
% Change period over period | 15.9 | % | 0.6 | % | 15.9 | % | 3.3 | % | ||||||||||
Following is a reconciliation of cash, cash equivalents and marketable
securities (GAAP) to adjusted cash, cash equivalents and marketable
securities (non-GAAP):
(in thousands) | March 31, 2019 | December 31, 2018 | |||||||
Cash, cash equivalents and marketable securities | $ | 452,535 | $ | 387,554 | |||||
Less: | |||||||||
Amounts payable for withheld federal and state income taxes, | |||||||||
employment taxes and other payroll deductions | 279,641 | 224,487 | |||||||
Client prepayments | 32,388 | 34,177 | |||||||
Adjusted cash, cash equivalents and marketable securities | $ | 140,506 | $ | 128,890 | |||||
Following is a reconciliation of operating expenses (GAAP) to adjusted
operating expenses (non-GAAP):
Three Months Ended March 31, | ||||||||||||||||||
(in thousands, except per WSEE per month) | 2019 | 2018 | ||||||||||||||||
$ | WSEE | $ | WSEE | |||||||||||||||
Operating expenses | $ | 141,256 | $ | 209 | $ | 135,017 | $ | 230 | ||||||||||
Less: | ||||||||||||||||||
One-time tax reform bonus | — | — | 9,306 | 16 | ||||||||||||||
Adjusted operating expenses | $ | 141,256 | $ | 209 | $ | 125,711 | $ | 214 | ||||||||||
% Change period over period | 12.4 | % | (2.3 | )% | 18.8 | % | 5.9 | % | ||||||||||
Following is a reconciliation of net income (GAAP) to EBITDA (non-GAAP)
and adjusted EBITDA (non-GAAP):
Three Months Ended March 31, | ||||||||||||||||||
(in thousands, except per WSEE per month) | 2019 | 2018 | ||||||||||||||||
$ | WSEE | $ | WSEE | |||||||||||||||
Net income | $ | 76,289 | $ | 113 | $ | 49,991 | $ | 85 | ||||||||||
Income tax expense | 10,736 | 16 | 15,098 | 26 | ||||||||||||||
Interest expense | 1,681 | 2 | 1,070 | 2 | ||||||||||||||
Depreciation and amortization | 6,691 | 10 | 5,213 | 9 | ||||||||||||||
EBITDA | 95,397 | 141 | 71,372 | 122 | ||||||||||||||
Stock-based compensation | 6,040 | 9 | 3,135 | 5 | ||||||||||||||
One-time tax reform bonus | — | — | 9,306 | 16 | ||||||||||||||
Adjusted EBITDA | $ | 101,437 | $ | 150 | $ | 83,813 | $ | 143 | ||||||||||
% Change period over period | 21.0 | % | 4.9 | % | 33.6 | % | 19.2 | % | ||||||||||
Following reconciliation of net income (GAAP) to adjusted net income
(non-GAAP):
Three Months Ended March 31, | ||||||||||
(in thousands) | 2019 | 2018 | ||||||||
Net income | $ | 76,289 | $ | 49,991 | ||||||
Non-GAAP adjustments: | ||||||||||
Stock-based compensation | 6,040 | 3,135 | ||||||||
One-time tax reform bonus | — | 9,306 | ||||||||
Total non-GAAP adjustments | 6,040 | 12,441 | ||||||||
Tax effect | (745 | ) | (2,886 | ) | ||||||
Adjusted net income | $ | 81,584 | $ | 59,546 | ||||||
% Change period over period | 37.0 | % | 54.1 | % | ||||||
Following is a reconciliation of diluted EPS (GAAP) to adjusted EPS (non-GAAP):
Three Months Ended March 31, | ||||||||||
2019 | 2018 | |||||||||
Diluted EPS | $ | 1.85 | $ | 1.18 | ||||||
Non-GAAP adjustments: | ||||||||||
Stock-based compensation | 0.15 | 0.07 | ||||||||
One-time tax reform bonus | — | 0.22 | ||||||||
Total non-GAAP adjustments | 0.15 | 0.29 | ||||||||
Tax effect | (0.02 | ) | (0.06 | ) | ||||||
Adjusted EPS | $ | 1.98 | $ | 1.41 | ||||||
% Change period over period | 40.4 | % | 53.3 | % | ||||||
The following is a reconciliation of GAAP to non-GAAP financial measures
for second quarter and full year 2019 guidance:
(in millions, except per share amounts) |
Q2 2019 Guidance |
Full Year 2019 Guidance |
|||||||
Net income | $28 – $30 | $167 – $178 | |||||||
Income tax expense | 11 – 12 | 48 – 50 | |||||||
Interest expense | 2 | 7 | |||||||
Depreciation and amortization | 7 | 28 | |||||||
EBITDA | 48 – 51 | 250 – 263 | |||||||
Stock-based compensation | 7 | 26 | |||||||
Adjusted EBITDA | $55 – $58 | $276 – $289 | |||||||
Diluted net income per share of common stock | $0.68 – $0.73 | $4.06 – $4.31 | |||||||
Non-GAAP adjustments: | |||||||||
Stock-based compensation | 0.18 | 0.63 | |||||||
Total non-GAAP adjustments | 0.18 | 0.63 | |||||||
Tax effect | (0.05 | ) | (0.14 | ) | |||||
Adjusted EPS | $0.81 – $0.86 | $4.55 – $4.80 |
Contacts
Investor Relations Contact:
Douglas S. Sharp
Senior
Vice President of Finance,
Chief Financial Officer and Treasurer
(281)
348-3232
[email protected]
News Media Contact:
Suzanne Haugen
Public
Relations Manager
(281) 312-3543
[email protected]
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Medical Cannabis Market Report 2024-2030: Asia-Pacific Set to Witness Robust Growth, Driven by R&D Discovery Initiatives
Cannabis
Rubicon Organics Reports Q1 2024 Financial Results
SCHWAZZE
Schwazze Announces First Quarter 2024 Financial Results
Schwazze Management to Host Conference Call Today at 5:00 p.m. Eastern Time
DENVER, May 15, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the first quarter ended March 31, 2024.
“We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico,” said Forrest Hoffmaster, Interim CEO of Schwazze. “Throughout the quarter, we continued to sharpen our pricing and promotional efforts while enhancing the in-store experience, widening assortment, improving in-stock position, and advancing our loyalty program to attract and retain new customers. We also strengthened our wholesale business with quarter-over-quarter growth, while surpassing 30% total door penetration across both states.”
“The Colorado market remains highly competitive with more than 680 active recreational licenses, underscoring the importance of delivering an exceptional customer experience and fully integrated retail support program. Although retail pricing has recently stabilized, Colorado sales in Q1 were down 10% year-over-year due to lower volumes. Nonetheless, we significantly outpaced the market as our sales were up 9%, demonstrating the effectiveness of our operating playbook to compete in challenging environments. We expect to continue driving improvements in customer acquisition, retention, and loyalty as we further increase market share in the state.”
“In New Mexico, the proliferation of new licenses continued to outpace state cannabis sales as store count in Q1 increased 31% year-over-year while the market grew only 13%. In addition to pricing and promotional efforts, we’ve focused on driving traffic into our stores by expanding assortment with high quality flower and delivering an elevated customer experience. The New Mexico regulatory body has also increased its license enforcement efforts in recent months, contributing to more than 70 store closures and a 33% sequential decrease in net new store openings in the first quarter. We will continue to support the New Mexico Cannabis Control Division as it develops its regulatory framework.”
“Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We are beginning to see positive momentum from our pricing and promotional strategy and will remain focused on driving operating efficiencies while further optimizing our assets as we consolidate cultivation facilities and eliminate underperforming stores that do not meet our high-margin thresholds. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward.”
First Quarter 2024 Financial Summary
$ in Thousands USD |
Q1 2024 |
Q4 2023 |
Q1 2023 |
Total Revenue |
$41,601 |
$43,325 |
$40,001 |
Gross Profit |
$17,934 |
$7,034[1] |
$21,849 |
Operating Expenses |
$20,643 |
$23,276 |
$16,199 |
Income (Loss) from Operations |
$(2,709) |
$(16,242) |
$5,650 |
Adjusted EBITDA[2] |
$7,341 |
$10,953 |
$14,525 |
Operating Cash Flow |
$(3,700) |
$3,452 |
$(880) |
Recent Highlights
- Announced the grand opening of a medical and recreational dispensary in March under the Everest Apothecary banner in Las Cruces, New Mexico, increasing the Company’s retail footprint to 34 stores across the state.
- Increased wholesale penetration in the first quarter to more than 30% of total doors in Colorado and New Mexico.
- Lowell Herb Co. pre-roll sales increased more than 3x quarter-over-quarter in Colorado, where it continues to be the #1 pre-roll in the state.
- Wana gummy sales up more than 2x quarter-over-quarter in New Mexico.
First Quarter 2024 Financial Results
Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period, partially offset by continued pricing pressure and the proliferation of new licenses in New Mexico.
Gross profit for the first quarter of 2024 was $17.9 million or 43.1% of total revenue, compared to $21.8 million or 54.6% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by the aforementioned pricing pressure in New Mexico, as well as higher medical sales mix in Colorado.
____________________________ |
1 Q4 2023 Gross Profit includes one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. |
Operating expenses for the first quarter of 2024 were $20.6 million compared to $16.2 million for the same quarter last year. The year-ago period benefitted from a payroll tax credit of $3.9M. The remaining increase was primarily driven by personnel expenses and four-wall SG&A costs associated with 21 additional stores in Colorado and New Mexico that are still ramping.
Loss from operations for the first quarter of 2024 was $2.7 million compared to income from operations of $5.6 million in the same quarter last year. Net loss was $16.1 million for the first quarter of 2024 compared to net income of $1.7 million for the same quarter last year.
Adjusted EBITDA for the first quarter of 2024 was $7.3 million compared to $14.5 million for the same quarter last year. The decrease in Adjusted EBITDA was primarily driven by lower gross margin and higher operating expenses associated with the 21 additional stores that are still ramping.
As of March 31, 2024, cash and cash equivalents were $13.2 million compared to $19.2 million on December 31, 2023. Total debt as of March 31, 2024, was $159.7 million compared to $156.8 million on December 31, 2023.
Conference Call
The Company will conduct a conference call today, May 15, 2024, at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.
Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].
Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call
The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.
Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910
If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.
About Schwazze
Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.
Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.
Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.
Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
For the Periods Ended March 31, 2024 and December 31, 2023
Expressed in U.S. Dollars
March 31, |
December 31, |
||||
2024 |
2023 |
||||
ASSETS
|
|||||
Current Assets |
|||||
Cash & Cash Equivalents |
$ |
13,151,317 |
$ |
19,248,932 |
|
Accounts Receivable, net of Allowance for Doubtful Accounts |
3,356,032 |
4,261,159 |
|||
Inventory |
26,382,184 |
25,787,793 |
|||
Marketable Securities, net of Unrealized Loss of $347,516 and Loss of $1,816, respectively |
108,583 |
456,099 |
|||
Prepaid Expenses & Other Current Assets |
3,502,310 |
3,914,064 |
|||
Total Current Assets |
46,500,426 |
53,668,047 |
|||
Non-Current Assets |
|||||
Fixed Assets, net Accumulated Depreciation of $10,061,700 and $8,741,782, respectively |
31,326,000 |
31,113,630 |
|||
Investments |
2,000,000 |
2,000,000 |
|||
Investments Held for Sale |
– |
202,111 |
|||
Goodwill |
67,492,705 |
67,499,199 |
|||
Intangible Assets, net Accumulated Amortization of $36,483,160 and $32,706,765, respectively |
162,391,482 |
166,167,877 |
|||
Other Non-Current Assets |
1,328,187 |
1,263,837 |
|||
Operating Lease Right of Use Assets |
34,575,832 |
34,233,142 |
|||
Deferred Tax Assets, net |
992,144 |
1,996,489 |
|||
Total Non-Current Assets |
300,106,350 |
304,476,285 |
|||
Total Assets |
$ |
346,606,776 |
$ |
358,144,332 |
|
LIABILITIES & STOCKHOLDERS’ EQUITY
|
|||||
Current Liabilities |
|||||
Accounts Payable |
$ |
9,443,233 |
$ |
13,341,561 |
|
Accrued Expenses |
8,106,618 |
7,774,691 |
|||
Derivative Liabilities |
1,319,845 |
638,020 |
|||
Lease Liabilities – Current |
5,186,316 |
4,922,724 |
|||
Current Portion of Long Term Debt |
29,579,713 |
3,547,011 |
|||
Income Taxes Payable |
28,235,039 |
25,232,782 |
|||
Total Current Liabilities |
81,870,764 |
55,456,789 |
|||
Non-Current Liabilities |
|||||
Long Term Debt, net of Debt Discount & Issuance Costs |
130,120,753 |
153,262,203 |
|||
Lease Liabilities – Non-Current |
30,735,072 |
30,133,452 |
|||
Total Non-Current Liabilities |
160,855,825 |
183,395,655 |
|||
Total Liabilities |
$ |
242,726,589 |
$ |
238,852,444 |
|
Stockholders’ Equity |
|||||
Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 82,185 Shares Issued and |
|||||
82,185 Outstanding as of March 31, 2024 and 85,534 Shares Issued and 85,534 Outstanding as of |
|||||
December 31, 2023. |
82 |
86 |
|||
Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 79,168,539 Shares Issued |
|||||
and 78,248,389 Shares Outstanding as of March 31, 2024 and 74,888,392 Shares Issued |
|||||
and 73,968,242 Shares Outstanding as of December 31, 2023. |
79,169 |
74,888 |
|||
Additional Paid-In Capital |
202,677,665 |
202,040,968 |
|||
Accumulated Deficit |
(96,843,602) |
(80,790,927) |
|||
Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of March 31, 2024 and |
|||||
920,150 Shares Held as of December 31, 2023. |
(2,033,127) |
(2,033,127) |
|||
Total Stockholders’ Equity |
103,880,187 |
119,291,888 |
|||
Total Liabilities & Stockholders’ Equity |
$ |
346,606,776 |
$ |
358,144,332 |
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars
For the Three Months Ended |
|||||
March 31, |
|||||
2024 |
2023 |
||||
(Unaudited) |
(Unaudited) |
||||
Operating Revenues |
|||||
Retail |
$ |
37,633,252 |
$ |
35,820,111 |
|
Wholesale |
3,898,320 |
4,058,925 |
|||
Other |
69,421 |
121,900 |
|||
Total Revenue |
41,600,993 |
40,000,936 |
|||
Total Cost of Goods & Services |
23,667,319 |
18,152,163 |
|||
Gross Profit |
17,933,674 |
21,848,773 |
|||
Operating Expenses |
|||||
Selling, General and Administrative Expenses |
11,835,818 |
10,100,934 |
|||
Professional Services |
1,671,881 |
1,187,364 |
|||
Salaries |
6,880,988 |
4,695,971 |
|||
Stock Based Compensation |
253,916 |
214,544 |
|||
Total Operating Expenses |
20,642,603 |
16,198,813 |
|||
Income from Operations |
(2,708,929) |
5,649,960 |
|||
Other Income (Expense) |
|||||
Interest Expense, net |
(8,307,369) |
(7,745,854) |
|||
Unrealized Gain (Loss) on Derivative Liabilities |
(681,825) |
8,501,685 |
|||
Other Loss |
10,500 |
– |
|||
Loss on Investment |
(33,382) |
– |
|||
Unrealized Gain on Investment |
(347,516) |
1,816 |
|||
Total Other Income (Expense) |
(9,359,592) |
757,647 |
|||
Pre-Tax Net Income (Loss) |
(12,068,521) |
6,407,607 |
|||
Provision for Income Taxes |
3,984,154 |
4,662,178 |
|||
Net Income (Loss) |
$ |
(16,052,675) |
$ |
1,745,429 |
|
Less: Accumulated Preferred Stock Dividends for the Period |
(2,155,259) |
(2,029,394) |
|||
Net Income (Loss) Attributable to Common Stockholders |
$ |
(18,207,934) |
$ |
(283,965) |
|
Earnings (Loss) per Share Attributable to Common Stockholders |
|||||
Basic Earnings (Loss) per Share |
$ |
(0.24) |
$ |
(0.01) |
|
Diluted Earnings (Loss) per Share |
$ |
(0.24) |
$ |
(0.06) |
|
Weighted Average Number of Shares Outstanding – Basic |
76,006,932 |
55,835,501 |
|||
Weighted Average Number of Shares Outstanding – Diluted |
76,006,932 |
101,608,278 |
|||
Comprehensive Income (Loss) |
$ |
(16,052,675) |
$ |
1,745,429 |
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars
For the Three Months Ended |
|||||
March 31, |
|||||
2024 |
2023 |
||||
(Unaudited) |
(Unaudited) |
||||
Cash Flows from Operating Activities: |
|||||
Net Income (Loss) for the Period |
$ |
(16,052,675) |
$ |
1,745,429 |
|
Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities |
|||||
Depreciation & Amortization |
5,096,314 |
6,151,395 |
|||
Non-Cash Interest Expense |
1,031,431 |
991,184 |
|||
Non-Cash Lease Expense |
2,871,226 |
2,251,459 |
|||
Deferred Taxes |
1,004,345 |
(637,225) |
|||
Loss on Investment |
202,111 |
– |
|||
Change in Derivative Liabilities |
681,825 |
(8,501,685) |
|||
Amortization of Debt Issuance Costs |
421,512 |
421,513 |
|||
Amortization of Debt Discount |
2,303,246 |
1,999,933 |
|||
(Gain) Loss on Investments, net |
347,516 |
(1,816) |
|||
Stock Based Compensation |
640,974 |
214,544 |
|||
Changes in Operating Assets & Liabilities (net of Acquired Amounts): |
|||||
Accounts Receivable |
905,127 |
(118,181) |
|||
Inventory |
(587,900) |
(3,023,251) |
|||
Prepaid Expenses & Other Current Assets |
411,754 |
(3,036,801) |
|||
Other Assets |
(64,350) |
360,674 |
|||
Change in Operating Lease Liabilities |
(2,348,703) |
(1,531,765) |
|||
Accounts Payable & Other Liabilities |
(3,566,401) |
(3,464,671) |
|||
Income Taxes Payable |
3,002,257 |
5,299,403 |
|||
Net Cash Provided by (Used in) Operating Activities |
(3,700,390) |
(879,861) |
|||
Cash Flows from Investing Activities: |
|||||
Collection of Notes Receivable |
– |
10,631 |
|||
Purchase of Fixed Assets |
(1,532,287) |
(2,913,394) |
|||
Net Cash Provided by (Used in) Investing Activities |
(1,532,287) |
(2,902,763) |
|||
Cash Flows from Financing Activities: |
|||||
Payment on Notes Payable |
(864,938) |
– |
|||
Net Cash Provided by (Used in) Financing Activities |
(864,938) |
– |
|||
Net (Decrease) in Cash & Cash Equivalents |
(6,097,615) |
(3,782,624) |
|||
Cash & Cash Equivalents at Beginning of Period |
19,248,932 |
38,949,253 |
|||
Cash & Cash Equivalents at End of Period |
$ |
13,151,317 |
$ |
35,166,628 |
|
Supplemental Disclosure of Cash Flow Information: |
|||||
Cash Paid for Interest |
$ |
4,515,205 |
$ |
6,540,748 |
MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars
For the Three Months Ended |
|||||
March 31, |
|||||
2024 |
2023 |
||||
Net Income (Loss) |
$ |
(16,052,675) |
$ |
1,745,429 |
|
Interest Expense, net |
8,307,369 |
7,745,854 |
|||
Provision for Income Taxes |
3,984,154 |
4,662,178 |
|||
Other (Income) Expense, net of Interest Expense |
1,052,223 |
(8,503,501) |
|||
Depreciation & Amortization |
5,618,834 |
6,612,814 |
|||
Earnings Before Interest, Taxes, Depreciation and |
|||||
Amortization (EBITDA) (non-GAAP) |
$ |
2,909,905 |
$ |
12,262,774 |
|
Non-Cash Stock Compensation |
253,916 |
214,544 |
|||
Deal Related Expenses |
637,761 |
1,195,802 |
|||
Capital Raise Related Expenses |
20,760 |
35,068 |
|||
Severance |
484,561 |
118,436 |
|||
Retention Program Expenses |
807,500 |
280,632 |
|||
Pre-Operating & Dark Carry Expenses |
1,053,837 |
391,917 |
|||
One-Time Legal Settlements |
417,653 |
– |
|||
Other Non-Recurring Items |
754,751 |
25,707 |
|||
Adjusted EBITDA (non-GAAP) |
$ |
7,340,644 |
$ |
14,524,880 |
|
Revenue |
41,600,993 |
40,000,936 |
|||
Adjusted EBITDA Percent |
17.6 % |
36.3 % |
View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-first-quarter-2024-financial-results-302146858.html
-
Cannabis1 week ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Cannabis2 weeks ago
IM Cannabis Reports First Quarter Financial Results
-
Innocan1 week ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis6 days ago
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
-
Cannabis6 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis5 days ago
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
-
Cannabis4 days ago
Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032
-
SCHWAZZE3 days ago
Schwazze Announces First Quarter 2024 Financial Results